Tracy McCarty
Investor Relations, BioMarin
Replay available
BioMarin Pharmaceutical Inc. (BMRN) Q2 2025 Earnings Call
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) Q2 2025 earnings conference call, held 2025-08-04. Replay captured from the company's public earnings webcast.
Hosted by
Featured presenters
Alexander Hardy
President & Chief Executive Officer
Brian Mueller
Executive Vice President & Chief Financial Officer
Kristen Hubbard
Executive Vice President & Chief Commercial Officer
Greg Freiberg
Executive Vice President & Chief R&D Officer
Paul Mateus
Analyst, Stiefel
Corey Kasimov
Analyst, Evercore
Akash Tiwari
Analyst, Jefferies
Investor webinar replay
Watch the replay and follow the connected company analysis, news, and investor updates for Biomarin Pharmaceutical Inc..
Replay transcript excerpt
WEBVTT 00:00:00.031 -- 00:00:03.696 All lines have been placed on mute to prevent any background noise. 00:00:03.696 -- 00:00:06.440 After the speaker's remarks, there will be a question and answer session. 00:00:06.440 -- 00:00:10.887 If you would like to ask a question during this time, simply press the star key, followed 00:00:10.887 -- 00:00:13.450 by the number one on your telephone keypad. 00:00:13.450 -- 00:00:16.354 If you would like to withdraw your question, press star one again. 00:00:16.354 -- 00:00:21.342 At this time, I'd like to turn the conference over to Tracy McCarty, Investor Relations 00:00:21.342 -- 00:00:23.244 at BioMarin. Please go ahead. 00:00:23.244 -- 00:00:24.727 Tracy 00:00:24.727 -- 00:00:29.217 McCarty Thank you, Operator. To remind you, this non-confidential presentation contains 00:00:29.217 -- 00:00:33.964 forward-looking statements about the business prospects of Biomarin Pharmaceutical, Inc., 00:00:33.964 -- 00:00:39.092 including expectations regarding Biomarin's financial performance, commercial products, 00:00:39.092 -- 00:00:43.960 and potential future products in different areas of therapeutic research and development. 00:00:43.960 -- 00:00:48.948 Results may differ materially depending on the progress of Biomarin's product programs, 00:00:48.948 -- 00:00:54.285 actions of regulatory authorities, availability of capital, future actions in the pharmaceutical 00:00:54.285 -- 00:00:59.230 market, and developments by competitors. And those factors detailed in Biomarin's filings 00:00:59.230 -- 00:01:04.415 with the Securities and Exchange Commission, such as 10Q, 10K, and 8K 00:01:04.415 -- 00:01:06.415 reports. 00:01:08.400 -- 00:01:12.944 In addition, we will use non-GAAP financial measures as defined in Regulation G during 00:0...